Tsai Capital Corp Abb Vie Inc. Transaction History

Tsai Capital Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$144.61 - $166.54 $43,383 - $49,962	-300 Reduced 14.29%	1,800 $286,000
Q4 2022 Feb 10, 2023	SELL	$138.31 - $165.87 $41,493 - $49,761	-300 Reduced 12.5%	2,100 $339,000
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $211,167 - $262,000	-1,600 Reduced 40.0%	2,400 $389,000
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $42,560 - $48,312	-400 Reduced 9.09%	4,000 $431,000
Q4 2020 Feb 11, 2021	BUY	$80.49 - $108.67 $354,156 - $478,148	4,400 New	4,400 $471,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Tsai Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Tsai Capital Corp with notifications on news.